Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections

作者：Giulano Christopher; Haase Krystal K; Hall Ronald^*

来源：Expert Review of Anti-Infective Therapy, 2010, 8(1): 95-106.

DOI：10.1586/ERI.09.123

• critically ill
• meningitis
• MIC
• MRSA
• obesity
• osteomyelitis
• pharmacodynamic
• pharmacokinetic
• pneumonia
• vancomycin

Vancomycin is a commonly used antimicrobial in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Increasing vancomycin MIC values in MRSA clinical isolates makes the optimization of vancomycin dosing pivotal to its continued use. Unfortunately, limited data exist regarding the optimal pharmacokinetic-pharmacodynamic (PK-PD) goal to improve bacterial killing and clinical outcomes with vancomycin. The hallmark study in this area suggests that achieving an AUC to MIC ratio of over 400 improves the likelihood of achieving these outcomes. Challenges in the implementation of PK-PD-based dosing for vancomycin include current methodologies utilized in microbiology laboratories, as well as intra- and interpatient pharmacokinetic variability. Individualized dosing based on MIC and specific patient factors is important to achieve optimal outcomes from vancomycin therapy.

• 出版日期2010-1